Dr. Jane Osbourn OBE - CHAIR

Dr. Jane Osbourn OBE

CHAIR

Jane has over 30 years of experience in biologics discovery and development. Most recently, she was Vice President for R&D and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology.

Jane is a scientific leader in the field of antibody engineering and has made a significant contribution to the discovery and development of eight marketed drugs and over 40 clinical candidates. Jane is passionate about science education and the development of the UK biotech sector and served as Chair of the Board of Directors of the BioIndustry Association for four years before taking on a Corporate Board Member role earlier this year. She is currently a Director of Babraham Bioscience Technologies, and also a Director of Cambridge Enterprise. She was awarded Scrip’s Lifetime Achievement Award and an OBE in 2019 for services to drug discovery, development and biotechnology.

Antibodies and Beyond: Sitting Down With… Jane Osbourn – The Medicine Maker featuring Dr. Jane Osbourn

Dr. Darrin M. Disley OBE - CEO

Dr. Darrin M. Disley OBE

CEO

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown, or invested in over 40 start-up life science, technology and social enterprises, raising $525 million USD in business financing and closing $650 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was awarded a lifetime Queen’s Award for Enterprise Promotion in 2016 for his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.

Chasing the Holy Grail of Cell Therapy  Labiotech featuring Dr. Darrin M. Disley 

Dr. Karin Schmitt - CBO

Dr. Karin Schmitt

CBO

Karin has over 25 years’ experience with a sustained track record of successful leadership roles within the life sciences, biotech and therapeutic industries at Exelixis, Inc., Millennium Pharmaceuticals, Thermo Fisher Scientific, Horizon Discovery Group plc and PredictImmune Ltd. Karin has brought over 20 innovative products to market internationally, across a wide scientific spectrum, with recent emphasis on clinical products and has additional experience in legal, commercial and regulatory pathways. Karin obtained her PhD in molecular biology at the University of Southern California in Los Angeles, followed by three years of post-doctoral research in genetics at the University of Cambridge.

Becoming a Successful Leader in the Life Sciences – Technology Networks featuring Dr. Karin Schmitt 

Joe Foster - COO

Joe Foster

COO

Joe began his career at Horizon Discovery Group plc working within the corporate development team gaining experience in business planning, licensing, technology evaluation and M&A analysis, before becoming Dr. Jonathan Milner’s (Co-founder of Abcam plc) Portfolio Manager where he built and managed a complex portfolio of more than 40 early-stage life science companies. Joe holds a degree in molecular and cellular biology from the University of Bath and an MPhil in business management from the University of Cambridge.

Leading the Movement Towards Direct Cell Conversion – Technology Networks featuring Joe Foster. 

Prof. Julian Gough - CSO (Co-founder)

Prof. Julian Gough

CSO (Co-founder)

Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.

Pierre-Louis Joffrin - CDO

Pierre-Louis Joffrin

Corporate Development Executive

Pierre-Louis has a background in biochemistry and pharmacology from the University of St Andrews and the University of Oxford. He previously worked in early stage venture development and investment at Oxford Sciences Innovations (OSI) and Deep Science Ventures (DSV) before becoming the first employee at Mogrify.

Cell Therapy – Falling short of its potential? – Drug Discovery World featuring Pierre-Louis Joffrin

Prof. Owen Rackham - CTO (Co-founder)

Prof. Owen Rackham

CTO (Co-founder)

Owen is world expert in the application of machine learning and complex systems in cell reprogramming. He was a career development fellow at the Medical Research Council, UK and was the recipient of a Japan Society for Promotion of Science fellowship to work at the RIKEN Omics Science Centre in Yokohama. He is now an Assistant Professor at the Duke-NUS Medical School in Singapore.

Prof. Jose Polo - CMO (Co-founder)

Prof. Jose Polo

CMO (Co-founder)

Jose has worked at the cutting-edge of cell reprogramming for over a decade. He graduated his PhD at the Albert Einstein College of Medicine in New York before becoming a research fellow at the Harvard Stem Cell Institute. He was awarded a NHMRC career development fellowship, a Charles Viertel Senior Medical Research fellowship as well as an ARC future fellowship and is now a Professor at Monash University.

Dr. Jane Osbourn OBE - CHAIR
Dr. Darrin M. Disley OBE - CEO
Dr. Karin Schmitt - CBO
Joe Foster - COO
Prof. Julian Gough - CSO (Co-founder)
Pierre-Louis Joffrin - Corporate Development Executive
Prof. Owen Rackham - CTO (Co-founder)
Prof. Jose Polo - CMO (Co-founder)

Our

Leadership Team

Dr. Jane Osbourn OBE - CHAIR

Dr. Jane Osbourn OBE

CHAIR

Jane has over 30 years of experience in biologics discovery and development. Most recently, she was Vice President for R&D and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology.

Jane is a scientific leader in the field of antibody engineering and has made a significant contribution to the discovery and development of eight marketed drugs and over 40 clinical candidates. Jane is passionate about science education and the development of the UK biotech sector and served as Chair of the Board of Directors of the BioIndustry Association for four years before taking on a Corporate Board Member role earlier this year. She is currently a Director of Babraham Bioscience Technologies, and also a Director of Cambridge Enterprise. She was awarded Scrip’s Lifetime Achievement Award and an OBE in 2019 for services to drug discovery, development and biotechnology.

Dr. Darrin M. Disley OBE - CEO

Dr. Darrin M. Disley OBE

CEO

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown or invested in over 40 start-up life science, technology and social enterprises, raising $525 million USD in business financing and closing $650 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was awarded a lifetime Queen’s Award for Enterprise Promotion in 2016 for his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.

Dr. Karin Schmitt - CBO

Dr. Karin Schmitt

CBO

Karin has over 25 years’ experience with a sustained track record of successful leadership roles within the life sciences, biotech and therapeutic industries at Exelixis, Inc., Millennium Pharmaceuticals, Thermo Fisher Scientific, Horizon Discovery Group plc and PredictImmune Ltd. Karin has brought over 20 innovative products to market internationally, across a wide scientific spectrum, with recent emphasis on clinical products and has additional experience in legal, commercial and regulatory pathways. Karin obtained her PhD in molecular biology at the University of Southern California in Los Angeles, followed by three years of post-doctoral research in genetics at the University of Cambridge.

Prof. Julian Gough - CSO (Co-founder)

Prof. Julian Gough

CSO (Co-founder)

Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.

Alice Newcombe-Ellis - Ahren Innovation Capital

ALICE NEWCOMBE-ELLIS

AHREN INNOVATION CAPITAL

Alice Newcombe-Ellis is the Founding & Managing Partner of Ahren Innovation Capital.

Alice has over a decade of investing experience, including at TPG Capital (leading global private equity firm with >$70BN AUM) and Lansdowne Partners (leading investment firm with >$15BN AUM). Her predominant investing focus has been in tech and disruptive healthcare.

Alice holds a Double First Class degree in mathematics, and Master’s in mathematics/physics from the University of Cambridge. She was a Fulbright Scholar and a Baker Scholar at Harvard Business School.

Alastair Kilgour - Parkwalk Advisors

ALASTAIR KILGOUR

PARKWALK ADVISORS

Representing Parkwalk Advisors, which he co-founded in 2009, Alastair was a Partner of Lazard LLP, Director of BNP and a Founder Partner of Ark Securities. He has analyzed and advised both private and public companies on strategy, development, fund-raising and exits. He oversees the investment process at Parkwalk and he sits on various portfolio company Boards, including Congenica, PhoreMost, PredictImmune, Aqdot and Mirriad.

Dr. Lorenz Mayr

DR. LORENZ MAYR

Observer

Dr. Mayr has over 30 years’ experience in biopharma research, development and commercialization. Most recently, he was Chief Technology Officer at GE Healthcare Life Sciences, where he was responsible for research investments, talent development and company growth strategy across all business areas. His former positions include Vice President & Global Head at AstraZeneca, where he oversaw the generation of biological reagents and assay development activities across all therapeutic areas, and Executive Director at Novartis.

Lorenze is a biochemistry lecturer at the Martin Luther University Halle-Wittenberg and has published over 60 peer-reviewed papers.

Dr. Jane Osbourn OBE - CHAIR
Dr. Darrin M. Disley OBE - CEO
Dr. Karin Schmitt - CBO
Prof. Julian Gough - CSO (Co-founder)
Alice Newcombe-Ellis - Ahren Innovation Capital
Alastair Kilgour - Parkwalk Advisors
Dr. Lorenz Mayr

Our

Board of directors